Predictors of coronavirus disease 2019 hospitalization after sotrovimab in patients with hematologic malignancy during the BA.1 Omicron surge Journal Article
| Authors: | Yan, J.; Steiger, S. N.; Kodama, R.; Fender, J.; Tan, C.; Laracy, J.; Cohen, N.; McMillen, T.; Jani, K.; Robilotti, E. V.; Babady, N. E.; Seo, S. K.; Kamboj, M. |
| Article Title: | Predictors of coronavirus disease 2019 hospitalization after sotrovimab in patients with hematologic malignancy during the BA.1 Omicron surge |
| Abstract: | BACKGROUND: Sotrovimab is an anti-spike neutralization monoclonal antibody developed to reduce the risk of coronavirus disease 2019 (COVID-19) progression and advancement to hospitalization in high-risk patients. Currently, there is limited research describing the association of sotrovimab treatment in patients with hematologic malignancy and the predictive factors of hospitalization. METHODS: We performed an observational study of 156 consecutive cancer patients who received sotrovimab at Memorial Sloan Kettering Cancer Center in New York City during the BA.1 Omicron surge. We evaluated the demographic, clinical, and laboratory characteristics of the patients who had subsequent COVID-19-related hospitalization(s) compared to those who did not. RESULTS: Among the 156 study patients, 17 (11%) were hospitalized, of whom 4 were readmitted for COVID-19-related complications; 3 deaths were attributed to COVID-19. Results from multivariable logistic regression show that significant factors associated with hospitalization include patients on anti-CD20 therapy (adjusted odds ratio [aOR], 5.59 [95% confidence interval {CI}, 1.73-18.12]; P = .004) and with relapse/refractory disease (aOR, 5.69 [95% CI, 1.69-19.16]; P = .005). Additionally, whole genome sequencing of severe acute respiratory syndrome coronavirus 2 detected high occurrences of mutations in the spike gene associated with treatment-related resistance longitudinal samples from 11 patients treated with sotrovimab. CONCLUSIONS: While sotrovimab is effective at reducing COVID-19 hospitalization and disease severity in patients with hematologic malignancy when administered early, patients who received anti-CD20 antibodies showed substantial morbidity. Due to the high potential for resistance mutation to sotrovimab and increased morbidity in patients on anti-CD20 therapy, combination treatment should be explored to determine whether it provides added benefits compared to monotherapy. Published by Oxford University Press on behalf of Infectious Diseases Society of America 2022. |
| Keywords: | neoplasm recurrence, local; monoclonal antibodies; hospitalization; hematologic malignancy; hematologic neoplasms; tumor recurrence; hematologic disease; complication; neutralizing antibody; antibodies, neutralizing; humans; human; covid-19; sars-cov-2; sotrovimab |
| Journal Title: | Clinical Infectious Diseases |
| Volume: | 76 |
| Issue: | 8 |
| ISSN: | 1058-4838 |
| Publisher: | Oxford University Press |
| Date Published: | 2023-04-15 |
| Start Page: | 1476 |
| End Page: | 1482 |
| Language: | English |
| DOI: | 10.1093/cid/ciac916 |
| PUBMED: | 36445792 |
| PROVIDER: | scopus |
| PMCID: | PMC11487148 |
| DOI/URL: | |
| Notes: | Article -- Export Date: 1 May 2023 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
Related MSK Work